Answers are grounded in this paper and cite their sources.
Phagocytosis and oxidative burst, induced through Rac GTPases and Toll-like receptors (TLRs), are central innate immune responses involved in inflammatory bowel disease (IBD) and colorectal cancer (CRC). However, their regulation in macrophages and involvement in colonic inflammation remain poorly characterized. We investigated Schlafen4 (Slfn4) using global and macrophage-specific Slfn4-deficient mice subjected to dextran sodium sulfate (DSS)-induced colitis and colitis-associated colorectal cancer (CAC). Gut microbiota alterations were assessed by 16S rRNA sequencing, fecal microbiota transplantation (FMT), and co-housing. Macrophage phagocytosis, ROS production, bacterial clearance, F-actin organization, and Rac1 activation were examined to define the underlying mechanism. We demonstrate that the upregulation of Slfn4 in macrophages upon TLR stimulation or bacterial infection is crucial for maintaining intestinal immune homeostasis. Global and macrophage-specific Slfn4 depletion exacerbated DSS-induced colitis and CAC, accompanied by gut microbiota dysbiosis. FMT and co-housing further supported the contribution of altered microbiota to aggravated colitis. Mechanistically, Slfn4 interacted with and activated Rac1 to remodel F-actin organization, thereby enhancing phagocytosis, ROS production, and bacterial clearance. Consequently, Slfn4-deficient macrophages exhibited impaired phagocytic and bactericidal activities, associated with disrupted barrier integrity and intestinal homeostasis. Notably, the Rac1 inhibitor NSC23766 counteracted the effects of Slfn4 deficiency. Slfn4 is an inducible regulator of macrophage innate immunity that promotes Rac1-dependent phagocytosis, ROS production, and bacterial clearance, thereby maintaining gut microbiota and intestinal homeostasis. Slfn4 protects against colitis and CAC and may represent a potential therapeutic target for IBD. Inflammatory bowel disease (IBD) causes chronic inflammation in the intestine and is closely associated with changes in gut bacteria. Macrophages are immune cells that protect the intestine by engulfing and killing harmful bacteria, but how this process is controlled remains unclear. In this study, we found that a protein called Schlafen4 (Slfn4) helps macrophages eliminate bacteria and maintain intestinal health. Mice lacking Slfn4 developed more severe intestinal inflammation and colitis-associated colorectal cancer, together with greater disruption of their gut bacteria. We found that Slfn4 activates Rac1, which helps macrophages engulf bacteria and produce reactive oxygen species needed for bacterial killing. Without Slfn4, these antibacterial functions were impaired, allowing intestinal microbial imbalance to worsen. Our findings reveal a previously unrecognized role for Slfn4 in linking macrophage antibacterial defense with gut microbiota homeostasis and suggest that this pathway may provide new opportunities for understanding and treating IBD.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: